TLR3: Toll-like receptor 3
Key component of innate and adaptive immunity.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on TLR3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Other 2
| Rintatolimod | Phase 3 | AIM ImmunoTech Inc. | Other | AgonistToll-like receptor 3 agonist | 4 |
| Bevasiranib | Phase 3 | OPKO Health | Oligonucleotide | ActivatorToll-like receptor 3 activator | 0 |
| Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer | Rintatolimod | Phase 2 | Not yet recruiting | Kalinski, Pawel, MD, PhD | Jun 8, 2026 |
| Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy | Rintatolimod | Phase 1 / Phase 2 | Active, not recruiting | Joachim Aerts, MD PhD | Jul 3, 2023 |
| Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery | Rintatolimod | Phase 2 | Active, not recruiting | Roswell Park Cancer Institute | Apr 2, 2019 |
| Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | Rintatolimod | Phase 1 / Phase 2 | Active, not recruiting | Robert Edwards | Nov 8, 2018 |
- Herpes simplex encephalitis0.63
- Hypothyroidism0.58
- Thyroid gland disorder0.55
- Venous thromboembolism0.48
- Hashimoto thyroiditis0.46
- Myxedema0.46
- Autoimmune thyroid disease0.44
- HIV-1 infection0.40
- Autoimmune disease0.37
- Inborn error of immunity0.37
- Age-related macular degeneration0.34
- Basal cell carcinoma0.34
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1075113, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt O15455, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets